New Cancer Drug Halves Disease Progression in Rare Tumor Patients
New drug bezuclastinib reduces rare cancer progression risk by 50% in clinical trials, offering hope to GIST patients with limited treatment options.
For rare cancer patients, who often feel forgotten by medical research focused on more common diseases, bezuclastinib's development demonstrates that innovative treatments can emerge even for smaller patient populations when research targets are precisely defined.
Key Facts
- 50% reduction in progression risk compared to control
- 16.5 month median progression-free survival
- 46% objective response rate in imatinib-resistant patients
- GIST affects 4,000-6,000 Americans annually
- Phase 3 trial results leading to regulatory submissions